300039.SZ深圳证券交易所 · 创业板 ChiNext
Shanghai Kaibao Pharmaceutical 上海凯宝
Traditional Chinese Medicine 中药Ⅱ
¥5.21+¥0.01 · +0.19%
Open 开盘
¥5.22
High 最高
¥5.30
Low 最低
¥5.15
Prev Close 昨收
¥5.20
Volume 成交量
2,339.3万股
Turnover 成交额
¥1.22亿
Mkt Cap 总市值
¥54亿
P/E 市盈率
21.1×
Recent Activity 近期动态All Filings 全部公告 →
5 significant filings since 30 May 2026: 2 on regulatory action and 3 on major holder buying. The latest, on 30 Jun 2026: 关于对上海证监局行政监管措施决定的整改报告. 1 unverified report logged, the latest on 5 Jun 2026.
自 30 May 2026 起有 5 份重大公告：regulatory action 2 份、major holder buying 3 份。最新一份（30 Jun 2026）：关于对上海证监局行政监管措施决定的整改报告。记录了 1 条未经核实的报道，最新一条见于 5 Jun 2026。
Price History 价格走势
1 session 个交易日, Thu 24 Sep 2026 · Live one-minute prices · High 最高 ¥5.30 · Low 最低 ¥5.16 · +0.19% on the previous close of ¥5.205.1755.2005.2255.2505.2755.300
Volume 成交量
1.6万
09:3010:3011:3014:0015:00
Overview 概览Deep Report 深度报告Financials 财务Valuation 估值Ownership 股东Analysts 券商Estimates 预测News 动态Events 事件Peers 同业
Relative Value 同业比较
Traditional Chinese Medicine 中药Ⅱ · 66 listed peers
| Measure 指标 | This Company 本公司 | Peer Median 同业中值 | Standing 排位 | |
|---|---|---|---|---|
| Market Cap 市值 | ¥54亿 | ¥61亿 | 32nd lowest of 66 · 66 家中第 32 低 | |
| Trailing P/E 市盈率 | 21.1x | 31.3x | 21st lowest of 49 · 49 家中第 21 低 | |
| P/B 市净率 | 1.3x | 2.2x | 10th lowest of 65 · 65 家中第 10 低 | |
| Revenue Growth 营收增速 | -23.4% | -7.4% | 10th lowest of 66 · 66 家中第 10 低 | |
| Profit Growth 净利增速 | -16.4% | -0.2% | 26th lowest of 66 · 66 家中第 26 低 | |
| Gross Margin 毛利率 | 80.2% | 56.9% | 2nd highest of 66 · 66 家中第 2 高 | |
| Net Margin 净利率 | 22.0% | 9.6% | 12th highest of 66 · 66 家中第 12 高 | |
| Return on Equity 净资产收益率 | 2.3% | 3.0% | 28th lowest of 65 · 65 家中第 28 低 | |
| Debt to Assets 资产负债率 | 6.7% | 28.4% | 3rd lowest of 66 · 66 家中第 3 低 | |
| Grade Score 评级得分 | 61 | 52 | 24th highest of 66 · 66 家中第 24 高 |
Statement figures are for the period to 30 Jun 2026, filed by 66 of 66 peers. A rank needs 5 or more peers with a value. A company with no earnings has no P/E. 报表数据为截至 30 Jun 2026 的期间，66 家同业中 66 家已披露。排位至少需要 5 家有数据的同业；无盈利的公司没有市盈率。
Largest Peers 主要同业
| Peer 同业 | Market Cap | P/E | P/B | Revenue Growth | Net Margin | ROE | Grade |
|---|---|---|---|---|---|---|---|
| Yunnan Baiyao Group 云南白药 | ¥890亿 | 17.0x | 2.2x | 2.9% | 16.9% | 9.0% | C |
| Zhangzhou Pientzehuang Pharmaceutical 片仔癀 | ¥708亿 | 39.1x | 4.8x | -15.0% | 23.7% | 7.3% | C |
| China Resources Sanjiu Medical 华润三九 | ¥389亿 | 11.9x | 1.7x | 1.4% | 13.3% | 7.3% | C |
| Beijing Tong Ren Tang 同仁堂 | ¥320亿 | 33.0x | 2.3x | -14.2% | 11.2% | 5.2% | D |
| Guangzhou Baiyunshan Pharmaceutical Holdings 白云山 | ¥315亿 | 12.3x | 0.8x | 0.6% | 5.1% | 5.4% | D |
| Dong-E-E-Jiao 东阿阿胶 | ¥289亿 | 16.2x | 2.8x | 3.4% | 27.3% | 8.1% | C |
| Tianjin Pharmaceutical Da Ren Tang 达仁堂 | ¥271亿 | 31.9x | 4.6x | -7.4% | 26.2% | 9.1% | C |
| Shijiazhuang Yiling Pharmaceutical 以岭药业 | ¥253亿 | 18.4x | 2.3x | 0.9% | 18.6% | 6.7% | B |
| Jumpcan 济川药业 | ¥225亿 | 12.2x | 1.6x | -15.3% | 33.6% | 5.3% | C |
| Jilin Aodong Pharmaceutical Group 吉林敖东 | ¥209亿 | 6.6x | 0.7x | -8.5% | 198.7% | 6.5% | C |
| Tasly 天士力 | ¥204亿 | 16.7x | 1.6x | -2.0% | 21.1% | 7.0% | C |
| Guangdong Zhongsheng Pharmaceutical 众生药业 | ¥198亿 | 99.6x | 5.0x | -23.0% | 10.7% | 2.7% | C |
| Kangmei Pharmaceutical 康美药业 | ¥184亿 | 624.3x | 2.5x | -11.1% | 1.6% | 0.5% | D |
| Buchang Pharma 步长制药 | ¥153亿 | 65.0x | 1.5x | -11.7% | 9.2% | 4.9% | D |
| Shanghai Kaibao Pharmaceutical 上海凯宝 | ¥54亿 | 21.1x | 1.3x | -23.4% | 22.0% | 2.3% | C |
Peers are listed by market cap, with this company highlighted. 同业按市值排列，本公司高亮显示。